George C. Clark - 06 Aug 2021 Form 3 Insider Report for Biohaven Pharmaceutical Holding Co Ltd.

Role
VP, Chief Accounting Officer
Signature
/s/ George C. Clark
Issuer symbol
N/A
Transactions as of
06 Aug 2021
Net transactions value
$0
Form type
3
Filing time
13 Aug 2021, 20:44:08 UTC
Next filing
26 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BHVN Common Shares 5,558 06 Aug 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BHVN Employee Stock Option (right to buy) 06 Aug 2021 Common Shares 10,000 $71.44 Direct F2
holding BHVN Employee Stock Option (right to buy) 06 Aug 2021 Common Shares 7,000 $83.38 Direct F3
holding BHVN Employee Stock Option (right to buy) 06 Aug 2021 Common Shares 8,250 $53.76 Direct F4
holding BHVN Employee Stock Option (right to buy) 06 Aug 2021 Common Shares 6,710 $32.42 Direct F5
holding BHVN Employee Stock Option (right to buy) 06 Aug 2021 Common Shares 1,250 $30.32 Direct F6
holding BHVN Restricted Share Unit Award 06 Aug 2021 Common Shares 20,000 Direct F7, F8, F9
holding BHVN Restricted Share Unit Award 06 Aug 2021 Common Shares 2,625 Direct F7, F9, F10
holding BHVN Restricted Share Unit Award 06 Aug 2021 Common Shares 2,000 Direct F7, F9, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This balance includes 700 shares and 288 shares that were acquired through the Biohaven Employee Share Purchase Plan on November 30, 2020 and May 31, 2021, respectively, and 200 shares held in an individual retirement account.
F10 The reporting person was granted 3,500 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date.
F11 The reporting person was granted 4,000 restricted share units on January 8, 2020, vesting in four equal installments on January 8, 2020, 2021, 2022 and 2023, subject to the reporting person's continued service with the Issuer at each vesting date.
F2 The shares underlying this option became exercisable as to 2,500 of these shares on May 7, 2021, with the remainder vesting in 3 equal installments on May 7, 2022, 2023, and 2024, subject to the reporting person's continuing service as of each applicable vesting date.
F3 The shares underlying this option became exercisable as to 1,750 of these shares on January 6, 2021, with the remainder vesting in 3 equal installments on January 6, 2022, 2023, and 2024, subject to the reporting person's continuing service as of each applicable vesting date.
F4 The shares underlying this option became exercisable as to 3,750 of these shares on and prior to December 5, 2020, with the remainder vesting in 2 equal installments on December 5, 2021, and 2022, subject to the reporting person's continuing service as of each applicable vesting date.
F5 The shares underlying this option became exercisable as to 960 of these shares on and prior to November 20, 2020, with the remainder vesting in 2 equal installments on November 20, 2021, and 2022, subject to the reporting person's continuing service as of each applicable vesting date.
F6 The shares underlying this option will vest on March 12, 2022, subject to the reporting person's continuing service as of each applicable vesting date.
F7 Each restricted share unit represents the contingent right to receive one common share of the Issuer.
F8 The reporting person was granted 20,000 restricted share units on May 7, 2021, vesting in four equal installments on May 7, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date.
F9 Not applicable.

Remarks:

Exhibit List: Exhibit 24: Power of attorney